Venus Medtech (Hangzhou) Inc.

SHSC:2500 Stock Report

Market Cap: HK$2.5b

Venus Medtech (Hangzhou) Management

Management criteria checks 1/4

Venus Medtech (Hangzhou)'s CEO is Lin Haosheng Lim, appointed in Dec 2016, has a tenure of 7.17 years. total yearly compensation is CN¥1.26M, comprised of 85.4% salary and 14.6% bonuses, including company stock and options. directly owns 0.72% of the company’s shares, worth HK$17.67M. The average tenure of the management team and the board of directors is 1.9 years and 2.9 years respectively.

Key information

Lin Haosheng Lim

Chief executive officer

CN¥1.3m

Total compensation

CEO salary percentage85.4%
CEO tenure7.2yrs
CEO ownership0.7%
Management average tenure1.9yrs
Board average tenure2.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Lin Haosheng Lim's remuneration changed compared to Venus Medtech (Hangzhou)'s earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

-CN¥1b

Mar 31 2023n/an/a

-CN¥1b

Dec 31 2022CN¥1mCN¥1m

-CN¥1b

Sep 30 2022n/an/a

-CN¥759m

Jun 30 2022n/an/a

-CN¥461m

Mar 31 2022n/an/a

-CN¥417m

Dec 31 2021CN¥1mCN¥694k

-CN¥374m

Compensation vs Market: Lin Haosheng's total compensation ($USD175.50K) is below average for companies of similar size in the Hong Kong market ($USD398.47K).

Compensation vs Earnings: Lin Haosheng's compensation has increased whilst the company is unprofitable.

CEO

Lin Haosheng Lim (49 yo)

7.2yrs

Tenure

CN¥1,263,000

Compensation

Mr. Hou-Sen Lim, also known as Lin Haosheng, MEng. Co-founded Transcatheter Technologies GmbH in 2009 and serves as its Managing Director and Chief Technology Officer. He serves as Chief Operating Officer...

Leadership Team

NamePositionTenureCompensationOwnership
Hou-Sen Lim
GM, COO & CTO7.2yrsCN¥1.26m0.72%
HK$ 17.7m
Fei Wang
Chief Financial Officerless than a yearno datano data
Joyce Heo
Director of Sales1.9yrsno datano data
Christopher Richardson
Head of U.S. Operations4.6yrsno datano data
Amir Gross
Head of Venus Global Heart Valve Innovation Center1.9yrsno datano data
Shakeel Osman
Senior Vice President of Sales Europe1.9yrsno datano data
Liu Meirong
Executive Director1.1yrsno datano data
Liqiao Ma
Executive Directorless than a yearno data0.0084%
HK$ 208.0k
Wai Chiu Wong
Company Secretary3.1yrsno datano data

1.9yrs

Average Tenure

49yo

Average Age

Experienced Management: 2500's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Liu Meirong
Executive Director1.1yrsno datano data
Liqiao Ma
Executive Directorless than a yearno data0.0084%
HK$ 208.0k
Martin B. Leon
Member of Advisory Boardno datano datano data
Chaim Lotan
Member of Global Advisory Board4.1yrsno datano data
Ting Yuk Wu
Independent Non-Executive Director5.3yrsCN¥423.00kno data
Chi Wai Suen
Independent Non-Executive Director4.6yrsCN¥335.00kno data
Wei Wang
Shareholders Representative Supervisor5.3yrsno datano data
Scott Lim
Member of Global Advisory Board4.1yrsno datano data
Min Shao
Employee Representative Supervisor1.5yrsno datano data
Zhang Ao
Non-Executive Director1.1yrsno datano data
Yue Li
Shareholders Representative Supervisor1.8yrsno datano data

2.9yrs

Average Tenure

48yo

Average Age

Experienced Board: 2500's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/02/19 01:09
End of Day Share Price 2023/11/22 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Venus Medtech (Hangzhou) Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wai Chak YuenBOCI Research Ltd.
Jin ZhangChina International Capital Corporation Limited
Haoyuan ZhangChina Merchants Securities (HK) Co., Ltd